ArticleRespiratory medicine
Assessment of the metabolome across the glucose tolerance spectrum in adults with cystic fibrosis hospitalized for pulmonary exacerbations.
Article in Respiratory medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics identification of amino acid and redox dysregulation in cystic fibrosis-related diabetes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCystic fibrosis-related diabetes (CFRD) is one of the most common co-morbidities among adults with cystic fibrosis (CF), yet the mechanisms determining its development remain unclear. This study explored the underlying biological mechanisms associated with CFRD development using plasma high-resolution metabolomics (HRM).
methodsThis cross-sectional study included 52 adults with CF hospitalized for a pulmonary exacerbation. Participants were categorized into three glucose tolerance groups: normal glucose tolerance (n = 26), pre-diabetes (n = 9), and CFRD (n = 17), based on data abstraction from the electronic medical record. Untargeted metabolomics were performed on fasted plasma using dual column liquid chromatography and high-resolution mass spectrometry. Analysis of covariates and pathway enrichment analysis were used to define the metabolites and pathways that differentiated between glucose tolerance groups. A sub-set analysis was performed using highest confidence metabolites quantified by reference standardization.
resultsAmong the 2134 features in HILIC and 1909 in C18 modes, glucose tolerance status was significantly associated with 94 and 107 features (p < 0.05), which were significantly enriched within three and eleven pathways, respectively. These pathways included redox-related processes, such as glutathione metabolism and the tricarboxylic acid cycle, as well as pentose phosphate pathway. In the sub-set analysis, two per- and polyfluoroalkyl substances were identified as decreasing with worsening glucose intolerance group (FDR q = 0.07 and 0.11, respectively). DISCUSSION: Untargeted metabolomics demonstrated several redox-related pathways differentiating between glucose tolerance categories among adults with CF during a pulmonary exacerbation. Future targeted research is warranted to determine biological mechanisms of CFRD pathophysiology, including the role of the environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.